| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6093
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6018
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-20 |
| filingDate |
2008-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2016-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2016-03-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-101600095-B1 |
| titleOfInvention |
Monoclonal anti beta amyloid antibody |
| abstract |
The present application relates to methods and compositions for the therapeutic and diagnostic use in the treatment of diseases and disorders caused by or associated with amyloid or amyloid-like proteins, including amyloidosis, disorders associated with amyloid proteins such as Alzheimer's disease, do. The present application provides novel methods and compositions comprising highly specific and highly effective antibodies having the ability to specifically recognize and bind to a particular epitope from a variety of beta-amyloid proteins. Antibodies enabled by the teachings of the present application are useful for the treatment of amyloid plaques including amyloidosis, i.e., secondary amyloidosis including but not limited to neurological disorders such as Alzheimer's disease (AD) and age-related amyloidosis. Lt; RTI ID = 0.0 > and / or < / RTI > amyloid or amyloid-like proteins comprising the group. |
| priorityDate |
2007-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |